Reviva Pharmaceuticals Holdings, Inc.
RVPH · NASDAQ
9/30/2025 | 6/30/2025 | 3/31/2025 | 12/31/2024 | |
|---|---|---|---|---|
| Revenue | $0 | $0 | $0 | $0 |
| % Growth | – | – | – | – |
| Cost of Goods Sold | $0 | $0 | $0 | $0 |
| Gross Profit | $0 | $0 | $0 | $0 |
| % Margin | – | – | – | – |
| R&D Expenses | $2 | $4 | $4 | $5 |
| G&A Expenses | $2 | $2 | $2 | $2 |
| SG&A Expenses | $2 | $2 | $2 | $2 |
| Sales & Mktg Exp. | $0 | $0 | $0 | $0 |
| Other Operating Expenses | $0 | $0 | $0 | $0 |
| Operating Expenses | $4 | $6 | $7 | $6 |
| Operating Income | -$4 | -$6 | -$7 | -$6 |
| % Margin | – | – | – | – |
| Other Income/Exp. Net | $0 | $0 | $0 | $0 |
| Pre-Tax Income | -$4 | -$6 | -$6 | -$6 |
| Tax Expense | $0 | $0 | $0 | $0 |
| Net Income | -$4 | -$6 | -$6 | -$6 |
| % Margin | – | – | – | – |
| EPS | -0.055 | -0.12 | -0.13 | -0.16 |
| % Growth | 54% | 7.7% | 18.8% | – |
| EPS Diluted | -0.055 | -0.12 | -0.13 | -0.16 |
| Weighted Avg Shares Out | 73 | 50 | 49 | 33 |
| Weighted Avg Shares Out Dil | 73 | 50 | 49 | 33 |
| Supplemental Information | – | – | – | – |
| Interest Income | $0 | $0 | $0 | $0 |
| Interest Expense | $0 | $0 | $0 | $0 |
| Depreciation & Amortization | $4 | $6 | $7 | -$1 |
| EBITDA | -$4 | -$6 | -$6 | -$6 |
| % Margin | – | – | – | – |